Epidermal Growth Factor Receptor Inhibition in Squamous Cell Carcinoma of the Head and Neck.
Overexpression of epidermal growth factor receptor (EGFR) is linked with poor prognosis in squamous cell carcinoma of the head and neck (SCCHN). Cetuximab binds specifically to EGFR with high affinity; combined with radiotherapy, it improves locoregional control and survival over radiotherapy alone. Adding cetuximab to platinum-based chemotherapy and 5-fluorouracil improves overall survival in incurable disease. Only a minority of patients benefit from anti-EGFR monoclonal antibodies. A better understanding of the molecular mechanisms involved in treatment resistance and identification of predictive biomarkers are crucial. Potentially more potent anti-EGFR compounds are currently under investigation with the aim of improving treatment efficacy.